Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Наслов
Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Идентификатор
/unibl/sci/idNaucniRad:36016
Тип
Пронађите сличне уносеAcademic Article
Датум
Пронађите сличне уносе2016-09
Библиографски цитат
LJ. Božić, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, Sep, 2016
Је дио
Пронађите сличне уносеSTED Journal
Пронађите сличне уносе2637-2150
Листа аутора
Position: 138115 (14 views)